Sign up to receive
Health Alerts via Email
Enter email address below:

To receive via RSS Feed
Click here:
RSS Feed
Free Our Health Care Now!

Contributors

  • Ron Bachman
  • Michael Bond
  • Jim Frogue
  • John Goodman
  • Linda Gorman
  • Robert Graboyes
  • John R. Graham
  • Devon Herrick
  • Regina Herzlinger
  • June O'Neill
  • Roy Ramthun
  • Greg Scandlen

Recent Posts


Blogroll


This is from the New York Times:

Eager to have a strong voice in the health care debate – and head off more draconian demands….. the pharmaceutical industry [has pledged] to contribute $80 billion in drug discounts and other savings over the next 10 years as a significant breakthrough on the road to health care reform.

The deal was negotiated in private among the industry, Senator Max Baucus, chairman of the Finance Committee and a crucial figure in shaping health reform, and the White House.

[However,] the Congress and the public should see these proposals as an opening bid and not the final word.

Bookmark and Share
5 Responses to “Lucy, Charlie Brown and the Football: The Drug Companies”
  1. Ken Says:

    The drug companies are more naive than Charlie Brown. I bet they got nothing in writing.

  2. Joe S. Says:

    I bet they don’t even have it on tape.

  3. Tom H. Says:

    Whatever they have, I bet it’s not notarized.

  4. Vicki Says:

    Whatever bad things happen to the drug companies, they will undoubtably deserve. Unfortunately it’s all the rest of us who will ultimately pay the price.

  5. Devon Herrick Says:

    The savings Max Baucus (Senate Finance chairman) hopes to achieve from drug maker discounts will prove to be illusory. The combination of modest deductibles and a coverage gap (i.e. donut hole) in Medicare Part D was designed to make the plans both affordable and beneficial to enrollees with a broad range of prescription drug needs. Part of the agreement requires drug makers to pay half the cost of name brand drugs for seniors throughout the Part D coverage gap. This will have the effect of making seniors less likely to switch to generic drugs. Since the government ultimately subsidizes about 75% of the cost of Part D plans, anything that reduces seniors’ incentive to substitute cheaper drugs will ultimately drive up the cost for taxpayers.

Leave a Reply